Perhaps most significantly, it enhanced the antitumor efficacy of engineered T cells while exhibiting favorable selective cytotoxicity (IC50 = 37.4 μM against tumor cells), thereby validating the therapeutic potential of IDO1 degradation in cancer immunotherapy. The gene discussed is IDO1; the disease is neoplasm.